Ensifentrine, a Novel Dual Phosphodiesterase (PDE) 3 and 4 Inhibitor, Improves Lung Function and Reduces Exacerbation Rate and Risk in Phase 3 Enhance-2 Trial

被引：0

作者：

Anzueto, A. ^{[1
]}

Barjaktarevic, I. ^{[2
]}

Rheault, T. ^{[3
]}

Bengtsson, T. ^{[4
]}

Rickard, K. ^{[3
]}

机构：

[1] Univ Texas Hlth Med San Antonio, Med Pulm Crit Care, San Antonio, TX USA

[2] UCLA, Pulm & Crit Care, Los Angeles, CA USA

[3] Verona Pharma, Raleigh, NC USA

[4] StatMind AB, Lund, Sweden

来源：

AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE | 2023年 / 207卷

关键词：

D O I：

暂无

中图分类号：

R4 [临床医学];

学科分类号：

1002 ; 100602 ;

摘要：

A4494

引用

页数：1

共 50 条

[1] Ensifentrine, a Novel Dual Phosphodiesterase (PDE) 3 and 4 Inhibitor, Improves Lung Function, Symptoms, Quality of Life and Reduces Exacerbation Rate and Risk in the Enhance-1 Phase 3 Trial of Ensifentrine in COPD
Sciurba, F. C.
Wise, R. A.
Rheault, T.
Bengtsson, T.
Rickard, K.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2023, 207
[2] ENSIFENTRINE, A NOVEL DUAL PHOSPHODIESTERASE (PDE) 3 AND 4 INHIBITOR, REDUCES EXACERBATION RATE AND RISK REGARDLESS OF EXACERBATION HISTORY IN POOLED ENHANCE TRIAL ANALYSES
Sciurba, Frank C.
Rheault, Tara
Bengtsson, Thomas
Rickard, Kathleen Ann
CHEST, 2023, 164 (04) : 5003A - 5004A
[3] Ensifentrine, a Dual Inhibitor of PDE3 and PDE4, Reduces the Risk of Exacerbation Regardless of Background Medication Use: A Sub-group Analysis of ENHANCE-2, a Phase 3 Trial
Ferguson, G. T.
Rheault, T.
Bengtsson, T.
Rickard, K.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2023, 207
[4] Ensifentrine, a Novel Dual Phosphodiesterase (PDE) 3 and 4 Inhibitor, Improves Lung Function, Symptoms, Quality of Life and Reduces Exacerbation Rate and Risk in Patients With COPD: Results From Replicate Phase 3 Trials
Sciurba, F. C.
Anzueto, A.
Rheault, T.
Bengtsson, T.
Rickard, K.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2023, 207
[5] Ensifentrine, a Novel Dual Phosphodiesterase (PDE) 3 and 4 Inhibitor, in Moderate and Severe COPD: Symptoms, Quality of Life and Health Status From the Phase 3 Trial Enhance-2
Rheault, T.
Bengtsson, T.
Rickard, K.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2023, 207
[6] Treatment With Ensifentrine, a Dual PDE3 and PDE4 Inhibitor, Significantly Reduced Exacerbation Rate and Risk in Subjects With COPD: Sub-group Results From the Phase 3 Trial, Enhance-2
Anzueto, A.
Rheault, T.
Bengtsson, T.
Rickard, K.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2023, 207
[7] Ensifentrine Reduced Healthcare Resource Utilization in Subjects With COPD: Results From Enhance-2, a Phase 3 Trial of Ensifentrine, a Dual PDE3/4 Inhibitor
Barjaktarevic, I.
Rheault, T.
Bengtsson, T.
Rickard, K.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2023, 207
[8] Ensifentrine, a Novel Dual Phosphodiesterase (PDE) 3 and 4 Inhibitor, Significantly Improves COPD Symptoms and Quality of Life in the Phase 3 Enhance-1 Trial
Sciurba, F. C.
Rheault, T.
Bengtsson, T.
Rickard, K.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2023, 207
[9] Ensifentrine, a Novel Dual Phosphodiesterase (PDE) 3 and 4 Inhibitor, Significantly Reduces Annualized Exacerbations and Delays the Time to First Exacerbation in COPD: Pooled Sub-Group Analyses of Enhance-1 and Enhance-2 Phase 3 Trials
Barjaktarevic, I.
Rheault, T.
Bengtsson, T.
Rickard, K.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2023, 207
[10] Safety Results From Dual PDE3/4 Inhibitor Ensifentrine: Gastrointestinal and Cardiovascular Safety From a 24-week Phase 3 Trial, Enhance-2
Siler, T. M.
Rickard, K.
Bengtsson, T.
Rheault, T.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2023, 207

← 1 2 3 4 5 →